MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Synthesis and pharmacological evaluation of 16-aryldieno steroids as anti-parkinsonian agents in LPS induced Neuroinflammation Model of Rat

    R. Bansal, R. Singh (Chandigarh, India)

    Objective: The present study is aimed at design and synthesis of new therapeutically useful steroidal neuroprotective derivatives as anti-parkinsonian agents. The new 16-aryldieno steroidal derivatives…
  • 2017 International Congress

    Role of the subthalamic nucleus and globus pallidus internus in response inhibition during masked prime tasks in human

    A. Singh, I. Niazi, V. Sharma, K. Boetzel (Minneapolis, MN, USA)

    Objective: To study the subthalamic nucleus (STN) and globus pallidus internus (GPi) local filed potential (LFP) activities in the response inhibition during masked prime tasks…
  • 2017 International Congress

    High-mobility group box 1 from astrocytes upregulates TH expression to maintain dopaminergic neurons via JNK pathway in human Parkinson’s disease patients and MPTP induced mouse model

    S.J. Kim, M.J. Ryu, J. Han, Y. Jang, J. Kim, M.J. Lee, I. Ryu, X. Ju, W. Chung, E. Oh, G.R. Kweon (Daejeon, Republic of Korea)

    Objective: Supporting by glial cells could be reinforced the function of dopaminergic neurons against extracellular insults in Parkinson’s disease (PD) development. However, we do not…
  • 2017 International Congress

    Correction of minimal oculomotor disorders improves forward and lateral axial dystonia in Pakinson’s disease

    S. Varanese, M. Meglio, M. Bologna, M. Santilli, G. Grillea, F. Lena, L. Meglio, N. Modugno (Pozzilli, Italy)

    Objective: To evaluate the possible improvement of lateral and forward axial dystonia in PD patients following correction of minimal oculomotor abnormalities including version and saccades…
  • 2017 International Congress

    CR6-interacting factor1 Deficiency in Dopamine Neurons Triggers Early-onset Parkinsonism in Mice

    I. Ryu, J. Han, Y. Jang, S.J. Kim, j. Kim, M.J. Lee, X. Ju, M.J. Ryu, S.-Y. Choi, W. Chung, E. Oh, G.R. Kweon (Daejeon, Republic of Korea)

    Objective: One candidate is CR6-interacting factor1 (CRIF1), which controls translation and membrane insertion of 13 mitochondrial proteins involved in oxidative phosphorylation. Here we determined the…
  • 2017 International Congress

    In silico predictive analytics: accelerating identification of potential disease-modifying compounds for Parkinson’s disease

    N. Visanji, A. Lacoste, S. Spangler, E. Argentinis, S. Ezell, C. Marras, L. Kalia (Toronto, ON, Canada)

    Objective: To use an in silico screen to identify compounds that have potential to reduce α-synuclein (aSyn) oligomers and are amenable to drug repurposing for…
  • 2017 International Congress

    Vitamin D in the Parkinson’s Associated Risk (PARS) Study

    M. Fullard, S. Xie, K. Marek, M. Stern, D. Jennings, A. Siderowf, A. Chen-Plotkin (Philadelphia, PA, USA)

    Objective: The purpose of this study was to evaluate vitamin D levels in a population at risk for developing Parkinson’s disease (PD). Background: Vitamin D…
  • 2017 International Congress

    Saccadic impairment in patients with Gaucher’s disease type 3

    J. Blume, C. Kämpe Björkvall, M. Machaczka, P. Svenningsson (Stockholm, Sweden)

    Objective: To characterize saccades in patients with chronic neuronopathic Gaucher’s disease (GD3) in relationship to their neurological and cognitive status using a computer-based eye-tracking technique.  Background: GD3 is…
  • 2017 International Congress

    A Pair of Brothers with Aceruloplasminemia Due to a Novel Nonsense Mutation: Unusual Phenotype and Neurological Improvement After Iron-Chelation Therapy with Deferasirox.

    F. Valzania, F. Cavallieri, M. Fiorini, S. Contardi, F. Ferrara, E. Menozzi, S. Scarlini, F. Cavalleri, M. Molinari, A. Pietrangelo, E. Corradini (Modena, Italy)

    Objective: We describe the phenotype of a novel ceruloplasmin mutation and the neurological response to different iron-chelating therapies. Background: Aceruloplasminemia (AC) is a rare autosomal…
  • 2017 International Congress

    Gait, Freezing of Gait and Falls detection using wearable sensors; a systematic review

    A.L. Silvade Lima, L.JW. Evers, T. Hahn, L. Bataille, J.L. Hamilton, M.A. Little, B.R. Bloem, M.J. Faber (Nijmegen, Netherlands)

    Objective: An overview of the use of wearable systems to assess gait, freezing of gait (FOG) and falls in patients with Parkinson’s disease (PD).  Background:…
  • « Previous Page
  • 1
  • …
  • 124
  • 125
  • 126
  • 127
  • 128
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25179 (not found)
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • Decision-making process for opicapone’s bedtime regimen
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley